 |
|
Should Statin Agents Be Administered to All Patients With Ischemic Stroke?
Arch Neurol. 2005;62:23-24.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Statin agents have revolutionized the management of atherosclerotic vascular disease.1-2 They have surpassed other classes of pharmacologic agents in the reduction of the incidence of myocardial infarction, stroke, and total mortality and, therefore, have been referred to as "miracle drugs."2 Not only do these drugs competitively inhibit 3-hydroxy-3-methyglutaryl coenzyme A, the last regulated reaction in the synthesis of cholesterol, but also they have non–lipid-lowering (pleiotropic) actions.2 For example, statins may upgrade endothelial nitric oxide synthase, inhibit inducible nitric oxide synthase, attenuate the inflammatory cytokine responses associated with cerebral ischemia, possess anti-oxidant properties, and modify endothelial function, plaque vulnerability, and thrombus formation. Because statin agents may reduce levels of C-reactive protein independent of low-density lipoprotein cholesterol lowering, it has been suggested that statins have important anti-inflammatory effects in addition to lipid-lowering effects.3
There has been debate in the neurologic community about whether statin agents should be used in every patient with . . . [Full Text of this Article] AUTHOR INFORMATION
Dilip K. Pandey, MD, PhD;
Philip B. Gorelick, MD, MPH
RELATED ARTICLE
Expanding Indications for Statins in Cerebral Ischemia: A Quantitative Study
Bruce Ovbiagele, Chelsea S. Kidwell, and Jeffrey L. Saver
Arch Neurol. 2005;62(1):67-72.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
Adams et al.
Stroke 2008;39:1647-1652.
FULL TEXT
|
